Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Recruiting 1Active not recruiting 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 146Thoracic 134Dermatologic 114Genitourinary 107Head & Neck 64Lymphoid 50CNS 36Sarcoma 30Gynecologic 27Breast 24Other solid neoplasm 21Other hematologic neoplasm 18Endocrine 18Tumor-Agnostic 15Plasma cell 15NET 10Myeloid 7Other neoplasm 2

Conditions

Tobacco Smoking 1Precancerous Conditions 1Malignant Neoplasms of Digestive Organs 1Head and Neck Neoplasms 1

Interventions

Cyclophosphamide 7fludarabine phosphate 6Peripheral Blood Stem Cell Transplantation 6Whole-Body Irradiation 5Tacrolimus 4Mycophenolic Acid 4Methotrexate 4Melphalan 4Busulfan 4Sulindac 3Paclitaxel 3Cyclosporine 3Cisplatin 3Capecitabine 3Biopsy 3Antilymphocyte Serum 3toripalimab 2sintilimab 2fludarabine 2Taxes 2Surveys and Questionnaires 2Specimen Handling 2Sirolimus 2Radiotherapy 2Patient Reported Outcome Measures 2Nivolumab 2Mesna 2Magnetic Resonance Spectroscopy 2Hyperthermic Intraperitoneal Chemotherapy 2Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2 × Nivolumab × Other neoplasm × Clear all
NCT03347838 2025-12-12

Nivolumab for the Reversal of Squamous Dysplasia in High Risk Current and Former Smokers

University of Colorado, Denver

Phase 2 Active not recruiting
19 enrolled 10 charts
Head & NeckOther neoplasm

Tobacco Smoking, Head and Neck Neoplasms, Precancerous Conditions

NCT05934331 2025-09-12

A LM-302 Combination With Other Anti-Tumor Therapies Phase ll Study

LaNova Medicines Limited

Phase 2 Recruiting
276 enrolled
Other neoplasm

Malignant Neoplasms of Digestive Organs

Data powered by HemOnc (CC BY 4.0) Colophon âš¡